The Medical Device Coordination Group (MDCG) shapes how medical devices are assessed in the European Union. One of its most influential documents is MDCG 2020-13, a guideline that explains how manufacturers should prepare Clinical Evaluation Reports (CERs) under the EU Medical Device Regulation (MDR). For any company aiming to place a device on the EU market, understanding MDCG 2020-13 for Manufacturers is essential.
Why MDCG 2020-13 Matters for Manufacturers
The MDR introduced a stricter and far more structured compliance framework. Clinical Evaluation Reports are no longer a formality—they are central to demonstrating safety, performance, and clinical benefit.
MDCG 2020-13 for Manufacturers provides the roadmap for building a CER that meets MDR expectations. Aligning with this guidance improves the quality of your Technical Documentation and significantly strengthens your chances of regulatory approval.
Clinical evaluation is now a continuous process, and MDCG 2020-13 ensures manufacturers understand what data to collect, how to justify it, and how to present it.
How MDCG 2020-13 Shapes the Clinical Evaluation Process (CER)
MDCG 2020-13 serves as a practical reference for structuring clinical evidence. It explains what the CER must include and aligns its structure with MDR Annex XIV, ensuring manufacturers remain fully compliant with current regulations.
The guideline helps manufacturers:
- Understand the level of clinical data required
- Present evidence in a regulatory‑ready format
- Show benefit‑risk alignment with MDR safety principles
For manufacturers, this guidance reduces ambiguity and supports consistent, defensible clinical evaluations.
What You Need to Know About Aligning CERs With the CEAR Format
Manufacturers may structure their Clinical Evaluation Report to follow the Clinical Evaluation Assessment Report (CEAR) used by Notified Bodies.
Why does this matter?
- It creates a smoother review process
- It improves clarity and traceability
- It anticipates NB expectations
Using the CEAR structure is not mandatory, but it can streamline regulatory interactions and reduce back‑and‑forth during conformity assessments.
Key Goals of the Clinical Evaluation Plan Under MDCG 2020‑13
MDCG 2020-13 reinforces the importance of a well‑defined Clinical Evaluation Plan (CEP). Manufacturers must align it with MDR Annex XIV Part A Section 1a. The CEP should clearly define:
✔ General Safety and Performance Requirements (GSPRs)
Identify which GSPRs require clinical evidence and describe how that evidence will be generated.
✔ Intended Purpose
Ensure consistency across the CER, IFU, labeling, and promotional materials.
✔ Target Populations and Indications
Include patient groups, contraindications, and specific clinical conditions.
✔ Clinical Benefits and Outcome Measures
Define measurable clinical outcomes linked to meaningful patient benefit.
✔ Clinical Safety Methods
Explain how both qualitative and quantitative aspects of safety will be assessed.
✔ Benefit‑Risk Parameters
List all metrics and criteria used to justify the benefit‑risk determination.
✔ Special Considerations for Combination Products
Address components such as medicinal substances, tissues of animal origin, or human derivatives.
✔ Clinical Development Plan
Include milestones and acceptance criteria—even if only high level.
A well‑designed CEP sets the foundation for a successful clinical evaluation and a strong CER.
Aligning IFU, Promotional Materials, and the CER Using MDCG 2020-13
One of the most practical aspects of MDCG 2020-13 for Manufacturers is its guidance on aligning all outward‑facing documents with the CER.
Here’s what manufacturers must evaluate:
Information Materials
Review IFUs, labeling, SSCPs, and promotional materials to ensure they reflect the evidence presented in the CER.
Intended Purpose
The intended purpose described in the CER must match exactly what appears in the IFU and promotional claims.
Patient Population and User Groups
Ensure consistency in population definitions and user profiles (HCP vs. lay user).
Warnings, Contraindications, and Precautions
Verify that safety information in the IFU is backed by data in the CER and risk management file.
Training Requirements
If user training is needed, justify this in both the risk management documentation and the CER.
Associated Risks and Residual Risks
Ensure risk descriptions align across the CER, IFU, PMS/PSUR, and RMF.
This alignment not only supports MDR compliance but also ensures safe, transparent communication to patients and users.
By aligning these documents in accordance with MDCG 2020-13, manufacturers not only assure compliance but also build a strong foundation for market success, bolstered by robust clinical evidence and transparent communication.
How to Incorporate these Aspects in Your Clinical Evaluation
1. Start With a Gap Analysis
Compare your existing CER and CEP against the MDCG 2020-13 requirements.
This identifies missing data, unclear claims, or inconsistencies.
2. Use a Multidisciplinary Team
Combine expertise from clinical, regulatory, engineering, and risk management.
This ensures your CER is scientifically sound and fully compliant.
3. Update Documentation
Revise the CEP, CER, and supporting Technical Documentation based on identified gaps.
4. Ensure Consistent Device Descriptions
Match the device description across the CER, IFU, marketing materials, and SSCP.
5. Integrate All Available Clinical Data
Include pre‑clinical data, clinical investigations, PMS results, PMCF findings, and real‑world evidence.
6. Leverage PMS and PSUR Insights
Use post‑market data to strengthen the CER and ensure continuous compliance.
7. Align With the Risk Management File
Make sure risk‑related statements remain consistent across all documents.
By taking these steps, manufacturers can confidently align with MDCG 2020-13, strengthen their clinical evidence, and support a smooth Notified Body review.
Why MDCG 2020-13 for Manufacturers Is a Strategic Advantage
This guideline is far more than a compliance requirement. It helps manufacturers:
- Build stronger, defensible clinical evidence
- Reduce regulatory delays
- Improve device safety and performance claims
- Strengthen market readiness
- Ensure consistent messaging across all documentation
With MDCG 2020-13, manufacturers can elevate the quality and credibility of their clinical evaluations—while accelerating time‑to‑market under the MDR.
